Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment

International Journal of Pharmaceutics

Volumn 400, Issue 1-2, 2010, Pages 194-200

  Wang, Junping ^a   Feng, Si Shen ^a   Wang, Shu ^a   Chen, Zhi ying ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biodegradable polymers; Chitosan; Gene therapy; Nanomedicine; Pharmaceutical nanotechnology; Polyethyleneimine (PEI)

Indexed keywords

CHITOSAN; DOUBLE STRANDED RNA; HEPATITIS B SURFACE ANTIGEN; MACROGOL; NANOPARTICLE; POLYETHYLENEIMINE; POLYGLACTIN; POLYLACTIDE; SMALL INTERFERING RNA;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HEPATITIS B; HUMAN; HUMAN CELL; NANOTECHNOLOGY; PRIORITY JOURNAL; SURFACE CHARGE; ZETA POTENTIAL;

CATIONS; CELL LINE; CHITOSAN; DNA; DRUG CARRIERS; GENE THERAPY; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; RNA, SMALL INTERFERING; SURFACE PROPERTIES; TRANSFECTION;

EID: 77957684389     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.08.026     Document Type: Article

References (30)

1. Ahn S.H., Chan H., Chen P.J., Cheng J., Goenka M.K., Hou J., Lim S.G., Omata M., Piratvisuth T., Xie Q., Yim H.J., Yuen M.F. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol. Int. 2010, 4(1):386-395.
2. Ashihara E., Kawata E., Maekawa T. Future prospect of RNA interference for cancer therapies. Curr. Drug Targets 2010, 11(3):345-360.
3. Chen Y., Cheng G., Mahato R.I. RNAi for treating hepatitis B viral infection. Pharm. Res. 2008, 25(1):72-86.
4. Cun D., Foged C., Yang M., Frøkjaer S., Nielsen H.M. Preparation and characterization of poly(d,l-lactide-co-glycolide) nanoparticles for siRNA delivery. Int. J. Pharm. 2010, 390(1):70-75.
5. Dong Y., Feng S.S. Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25(14):2843-2849.
6. Guo J., Fisher K., Darcy R., Cryan J.F., O'Driscoll C Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Mol. Biosyst. 2010, 6(7):1143-1161.
7. Hart S.L. Multifunctional nanocomplexes for gene transfer and gene therapy. Cell Biol. Toxicol. 2010, 26(1):69-81.
8. Hombach J., Bernkop-Schnürch A. Chitosan solutions and particles: evaluation of their permeation enhancing potential on MDCK cells used as blood brain barrier model. Int. J. Pharm. 2009, 376(1-2):104-109.
9. Kim I.S., Lee S., Park Y.M., Lee Y.B., Shin S.C., Lee K.C., Oh I.J. Physicochemical characterization of poly(l-lactic acid) and poly(d,l-lactide-co-glycolide) nanoparticles with polyethylenimine as gene delivery carrier. Int. J. Pharm. 2005, 298(1):255-262.
10. Lee S.H., Kim S., Park T.G. Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem. Biophys. Res. Commun. 2007, 357(2):511-516.
11. Li Y., Wasserb S., Lim S.G., Tan T.M. Genome-wide expression profiling of RNA interference of hepatitis B virus gene expression and replication. Cell. Mol. Life Sci. 2004, 61(16):2113-2124.
12. Martinez M.A. Progress in the therapeutic applications of siRNAs against HIV-1. Methods Mol. Biol. 2009, 487:343-368.
13. Ma Y., Chan C., He M.L. RNA interference and antiviral therapy. World J. Gastroenterol. 2007, 13(39):5169-5179.
14. Malmström S., Hannoun C., Lindh M. Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan PCR. J. Virol. Methods 2007, 143(2):147-152.
15. Mu L., Feng S.S. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 2003, 86(1):33-48.
16. Munier S., Messai I., Delair T., Verrier B., Ataman-Onal Y. Cationic PLA nanoparticles for DNA delivery: comparison of three surface polycations for DNA binding, protection and transfection properties. Colloids Surf. B Biointerfaces 2005, 43(3-4):163-173.
17. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endolysosomal escape of poly(d,l-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002, 16:1217-1226.
18. Prabha S., Zhou W.Z., Panyam J., Labhasetwar V. Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int. J. Pharm. 2002, 244:105-115.
19. Radhakrishnan S.K., Layden T., Gartel AL RNA interference as a new strategy against viral hepatitis. Virology 2004, 323(2):173-181.
20. Ravi Kumar M.N., Bakowsky U., Lehr C.M. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25(10):1771-1777.
21. Schiffelers R.M., Ansari A., Xu J., Zhou Q., Tang Q., Storm G., Molema G., Lu P.Y., Scaria P.V., Woodle M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32(19):149.
22. Song X., Hu Z., Zhang H. Acute dystonia induced by lamivudine. Clin. Neuropharmacol. 2005, 28(4):193-194.
23. Verma N.K., Dey C. RNA-mediated gene silencing: mechanisms and its therapeutic applications. J. Clin. Pharm. Ther. 2004, 29(5):395-404.
24. Vial T., Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994, 10:115-150.
25. Wilson R., Purcell D., Netter H.J., Revill P.A. Does RNA interference provide new hope for control of chronic hepatitis B infection?. Antivir. Ther. 2009, 14(7):879-889.
26. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26(15):2713-2722.
27. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K., Rajeev K.G., Nakayama T., Charrise K., Ndungo E.M., Zimmermann T., Koteliansky V., Manoharan M., Stoffel M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 2007, 25(10):1149-1157.
28. Wu J., Nandamuri K. Inhibition of hepatitis viral replication by siRNA. Expert Opin. Biol. Ther. 2004, 4(10):1649-1659.
29. Xing J., Deng L., Guo S., Dong A., Liang X.J. Polycationic nanoparticles as nonviral vectors employed for gene therapy in vivo. Mini Rev. Med. Chem. 2010, 10(2):126-137.
30. Zhang Z., Feng S.S. Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 2006, 27(2):262-270.